Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Per Ljungman , Gloria Tridello , Jose Luis Piñana , Fabio Ciceri , Henrik Sengeloev , Alexander Kulagin , Stephan Mielke , Zeynep Arzu Yegin , Matthew Collin , Sigrun Einardottir , Sophie Ducastelle Lepretre , Johan Maertens , Antonio Campos , Elisabetta Metafuni , Herbert Pichler , Frantisek Folber , Carlos Solano , Emma Nicholson , Meltem Kurt Yüksel , Kristina Carlson , Beatriz Aguado , Caroline Besley , Jenny Byrne , Immaculada Heras , Fiona Dignan , Nicolaus Kröger , Christine Robin , Anjum Khan , Stig Lenhoff , Anna Grassi , Veronika Dobsinska , Nuno Miranda , Maria-Jose Jimenez , Ipek Yonal-Hindilerden , Keith Wilson , Dina Averbuch , Simone Cesaro , Alienor Xhaard , Nina Knelange , Jan Styczynski , Malgorzata Mikulska , Rafael de la Camara Frontiers in immunology（2023）
摘要
Although the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.
更多 查看译文
关键词
CMV, COVID-19, allogeneic, risk factors, stem cell transplantation
AI 理解论文
溯源树
样例
